LLY
Lilly’s trying to make one drug duo do double duty
Eli Lilly is out with new exploratory Phase 3b data from the TOGETHER-PsO study, looking at how Taltz (ixekizumab) and Zepbound (tirzepatide) play together in adults with psoriasis and obesity or overweight.
That’s a pretty neat trick if you’re Lilly: take a blockbuster immunology drug and a blockbuster obesity drug, then see whether the combo can prove useful beyond the obvious. It’s not exactly a Marvel crossover, but it does hint at how the company wants to stitch together its immune and metabolic businesses into something bigger than the sum of its parts.
Why investors should care
For shareholders, the big question isn’t just “did the study look interesting?” It’s whether Lilly can keep expanding the reach of its pipeline while the Zepbound machine is already printing growth and Taltz keeps its own franchise relevant.
This kind of exploratory data can help:
- support future clinical development paths
- reinforce Lilly’s obesity-plus-comorbidity narrative
- give doctors and investors more confidence that the company’s pipeline has range, not just one hit song
The bigger Lilly playbook
Lilly has been leaning hard into the idea that obesity medicine isn’t a one-and-done market. If you can tie weight loss to inflammation, cardiovascular risk, diabetes, and other comorbidities, suddenly the addressable market gets a lot less sleepy.
So while this isn’t a headline-grabbing approval or a giant trial win, it does fit the broader storyline: Lilly keeps finding ways to make its already-hot assets look even more valuable.
Big picture: the stock story here is less “one more data release” and more “Lilly keeps building a wider moat around the obesity and immunology empire.”